Tablets of Avigan (generic name : Favipiravir), a drug approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity at Fujifilm’s headquarters in Tokyo October 22, 2014. Japan’s Fujifilm Holdings Corp said on Monday it was expanding the production of its Avigan anti-influenza drug to reach an additional number of Ebola patients. France and Guinea plan to conduct clinical trials of Avigan 200 mg tablets, made by Fujifilm group company Toyama Chemical Co, in Guinea to treat Ebola in mid-November, Fujifilm said in a statement. (REUTERS/Issei Kato)
France said on Wednesday the first trials of a drug to treat Ebola in Guinea had been encouraging and appeared to accelerate the recovery process of patients, President Francois Hollande’s office said in a statement.
Trials of an experimental Japanese drug – Avigan, or favipiravir – developed by Toyama Chemical, a subsidiary of Japan’s Fujifilm, began at a treatment center in Guinea in mid-December.
“The results are encouraging. They show a fall in the number of deaths in adults and teenagers. The recovery process is accelerated,” Hollande’s office said after he met doctors working on tackling Ebola. It added the treatment was given to 80 patients, adults and children.
By Chernor Ojuku Sesay Cocorioko Correspondent in Freetown Wednesday December 14, 2005 Dr. Abass Bundu yesterday disclosed to journalists at a press conference at SLENA headquarters in Freetown, that he never […]
By State House Communications Unit President Dr Ernest Bai Koroma this morning (Thursday, 11th September) got a courtesy call from the UN Ebola Response Coordinator, Dr David Nabarro at State […]
COCORIOKO is produced in Somerset, Franklin Township , New Jersey , USA and Brookfields , Freetown, Sierra Leone. The sole owner, financier , Publisher and Chief Executive Officer ( CEO ) is the Rev. Leeroy Wilfred Kabs-Kanu. All matters pertaining to the paper should be directed to the CEO, Rev. Kabs-Kanu at email@example.com. No article or any part of this website should be reproduced without the expressed permission of the Publisher.